Join
Live feed
·
NEWSReleasevia Quantisnow
NanoViricides Inc. logo

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

ByQuantisnow·Wall Street's wire, on your screen.
NNVC· NanoViricides Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NNVC (NanoViricides Inc.) and more on Quantisnow.